Table 3 Summary of solicited adverse events safety population.
ChAdOx1 nCoV-19 Prime cohort | BBV152 Prime cohort | |||
|---|---|---|---|---|
SII-NVX-CoV2373 (N = 92) n (%) [E] | ChAdOx1 nCoV-19 (N = 94) n (%) [E] | SII-NVX-CoV2373 (N = 92) n (%) [E] | BBV152 (N = 94) n (%) [E] | |
Participants with at Least One Solicited Adverse Event | 33 (35.9) [69] | 29 (30.9) [61] | 34 (37.0) [84] | 43 (45.7) [87] |
Participants with at Least One Local Solicited AE | 18 (19.6) [26] | 24 (25.5) [28] | 20 (21.7) [29] | 36 (38.3) [43] |
Injection Site Pain | 17 (18.5) [17] | 24 (25.5) [24] | 20 (21.7) [20] | 35 (37.2) [35] |
Injection Site Tenderness | 5 (5.4) [5] | 3 (3.2) [3] | 4 (4.3) [4] | 6 (6.4) [6] |
Injection Site Swelling | 3 (3.3) [3] | 0 | 3 (3.3) [3] | 1 (1.1) [1] |
Injection Site Erythema | 1 (1.1) [1] | 0 | 1 (1.1) [1] | 0 |
Injection Site Induration | 0 | 1 (1.1) [1] | 1 (1.1) [1] | 1 (1.1) [1] |
Participants with at Least One Systematic Solicited AE | 24 (26.1) [43] | 17 (18.1) [33] | 25 (27.2) [55] | 25 (26.6) [44] |
Headache | 12 (13.0) [12] | 11 (11.7) [11] | 13 (14.1) [13] | 9 (9.6) [9] |
Arthralgia | 7 (7.6) [7] | 6 (6.4) [6] | 5 (5.4) [5] | 5 (5.3) [5] |
Fatigue | 7 (7.6) [7] | 6 (6.4) [6] | 11 (12.0) [11] | 11 (11.7) [11] |
Malaise | 5 (5.4) [5] | 4 (4.3) [4] | 12 (13.0) [12] | 7 (7.4) [7] |
Myalgia | 5 (5.4) [5] | 3 (3.2) [3] | 7 (7.6) [7] | 5 (5.3) [5] |
Fever | 5 (5.4) [5] | 0 | 4 (4.3) [4] | 4 (4.3) [4] |
Vomiting | 1 (1.1) [1] | 2 (2.1) [2] | 1 (1.1) [1] | 1 (1.1) [1] |
Nausea | 1 (1.1) [1] | 1 (1.1) [1] | 2 (2.2) [2] | 2 (2.1) [2] |
